The value of pre-treatment with gonadotrophin releasing hormone (GnRH) analogue in IVF-ET therapy of severe endometriosis
- 1 May 1990
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 5 (4) , 418-420
- https://doi.org/10.1093/oxfordjournals.humrep.a137114
Abstract
Controversy concerning the optimal treatment of endometriosis and its related infertility still exists. Thirty-one women with moderate and severe endometriosis, who failed to conceive during previous in-vitro fertilization and embryo transfer (IVF-ET) cycles (protocol A), were re-admitted for the procedure following a period of hormonal suppression with a gonadotrophin releasing-hormone (GnRH) agonist (protocol B). Following GnRH analogue treatment, a significantly higher number of oocytes were recovered (P < 0.0006); consequently more embryos were transferred and significantly higher clinical pregnancy rates per cycle (P < 0.0001) were achieved. This difference may be directly related to the beneficial effect of the GnRH analogue on pelvic endometriosis, converting severe cases into mild ones with improved ovarian accessibility and probably oocyte quality.Keywords
This publication has 0 references indexed in Scilit: